TransEnterix installs Senhance Robotic System Programme at Imperial College London and Imperial College Healthcare NHS Trust.
M2 PHARMA-November 10, 2016-TransEnterix installs Senhance Robotic System Programme at Imperial College London and Imperial College Healthcare NHS Trust
(C)2016 M2 COMMUNICATIONS
Medical device company TransEnterix (NYSE MKT:TRXC) stated on Wednesday that its Senhance Robotic Surgical System has been installed at Imperial College London and St. Mary's Hospital of the Imperial College Healthcare NHS Trust.
The company added that the Senhance is the first surgical system that brings haptic force feedback, eye-sensing camera control, and responsible economics through reusable instrumentation to robotics.
Imperial College London and the Imperial College Healthcare NHS Trust are among the leading centres for minimally invasive surgical innovation in the world, said Todd M. Pope, president and CEO at TransEnterix. They have chosen to add the Senhance system to their MIS programme in general and colorectal surgery.
According to TransEnterix, the medical device company is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 10, 2016|
|Previous Article:||FDA Clears Joimax's Vaporflex, Legato Electrosurgical Probes.|
|Next Article:||RegeneRx Biopharmaceuticals enrols first patients in ARISE-2 trial of RGN-259.|